Powered by ZigaForm version

Public Alert No. 016/2022 – Substandard Cozol Suspension (Manufactured By M/S. Alkemy Pharmaceutical Laboratories (PVT.) Ltd. Hyderabad) Pakistan

March 24, 2022,

The National Agency for Food and Drug Administration and Control is notifying the healthcare providers and the public that Drug Regulatory Authority of Pakistan (DRAP) and CDL Karachi Pakistan has declared “Cozol Suspension” batch E206 as a substandard drug and has been recalled from circulation.

 Details of the Affected product

Product Name Active


Manf date Expiry Date Batch No Manufacturer
Cozol Suspension


Trimethoprim and Sulphhamethoxazole Sep 2021 Aug 2024 E-206 Alkemy Pharmaceutical Laboratories (Pvt.) Ltd. Hyderabad) Pakistan.


All medical products must be obtained from licensed, authentic, and reliable sources. Their authenticity and condition should be carefully checked

NAFDAC requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this substandard product batch.

If anyone has used this substandard product batch or suffer an adverse reaction/event having used this product batch, it is advised to seek immediate medical advice from a qualified healthcare professional.

Members of the public already in possession of the above stated product batch are implored to discontinue sale or use and handover stock to the nearest NAFDAC office.

Healthcare professionals and consumers are encouraged to report adverse events or side effects related to the use of the product to the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLL FREE from all networks), via pharmacovigilance@nafdac.gov.ng or via the NAFDAC ADR e-Reporting platform available at www.nafdac.gov.ng

NAFDAC……..Customer-focused, Agency-minded!!!

Signed Management

Was this post helpful?